MONARCH 3: OS Update - Slideset Download - ESMO Congress Paris | CCO
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups | npj Breast Cancer
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer | Breast Cancer
Carlo Palmieri on X: "MONARCH 3 Final Overall Survival: No statistical improvement in OS ❌ but OS was improved by median 13 month favouring abemaciclib arm. Data for ribociclib/MONALEESA-2 shown for comparison
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials - Toi - 2021 - Cancer Science - Wiley Online Library
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy | npj Breast Cancer
Final overall survival analysis from the MONARCH 3 study of Verzenio (abemaciclib) presented at the 2023 San Antonio Breast Cancer Symposium - Medthority
Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer - European Medical Journal
Journal of Clinical Oncology on X: "MONARCH 3 trial: Abemaciclib as initial therapy for advanced breast cancer https://t.co/YlEshSmVC7 #bcsm https://t.co/3hGY4XRWHd" / X
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer
Carlo Palmieri (@cancermedic) / X
![PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1b316b998a6f3d4685942edb98b16960acc9a40c/5-Figure4-1.png "PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 | Semantic Scholar")
PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 | Semantic Scholar
Kaplan–Meier curve for overall survival in the premenopausal population... | Download Scientific Diagram
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant | Breast Cancer Research | Full Text
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Progression-free survival. PFS analysis at the February 14, 2017 data... | Download Scientific Diagram
Abemaciclib regimen shows further signs of benefit in advanced breast cancer subgroup
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant | Breast Cancer Research | Full Text
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. | Semantic Scholar
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer
Abemaciclib plus aromatase inhibitor in advanced breast cancer
Archive | ESMO
Kaplan-Meier curves for progression-free survival in the premenopausal... | Download Scientific Diagram
